Abstract:Astaxanthin is a xanthophyll carotenoid, well known for its potent anti-inflammatory and antioxidant properties, owing to its unsaturated molecular structure. Aquatic plants and animals contain the hydrophobic carotenoid astaxanthin, which is thought to possess a number of advantageous biological traits. However, due to its weak bioavailability and low water solubility, its use as a nutraceutical in food is currently restricted. Cubosomal encapsulation has been considered an effective alternative for improving the bioavailability and solubility of hydrophobic bioactives. The current paper aimed to conquer these issues by encapsulating astaxanthin in lyotropic liquid crystal nano-formulations prepared via the fabrication method. The physicochemical properties of astaxanthin-loaded cubosomes (AST-LC) have also been analyzed, in order to know the morphology of the prepared formulations and their bioavailability in the biological system. The formulation has been tested for particle size, thermal behavior, zeta potential, crystallinity, encapsulation efficiency, and drug-polymer interactions. The observed experimental results showed the particle size and zeta potential of astaxanthin-loaded cubosomes (AST-LC) as 199 ± 0.23 nm −27.4 ± 4.67 mV, with a small polydispersity index (0.283 ± 1.01). The cubic structure and nano-range size of the ideal formulation were verified by a field emission scanning electron microscope (FESEM) and (HRTEM) high-resolution transmission electron microscopic examination. The formulation exhibits a higher encapsulation efficiency with good yield. Results from X-ray diffraction and diffraction scanning calorimetry demonstrated an amorphous state of astaxanthin incorporated into the formulation. Fourier transform infrared spectroscopy (FTIR) analysis of AST-LC showed the absence of astaxanthin main peaks, indicating its complete encapsulation inside the formulation. The drug–excipient interaction was carried out with diffraction scanning calorimetry DSC and FTIR, resulting in no interaction between them. These results offered important details about increasing astaxanthin bioavailability by incorporating it into cubosomes. Furthermore, the astaxanthin loaded into cubosomes has been evaluated for antioxidant potency, compared with astaxanthin extract using 2,2-diphenylpicrylhydrazylassay (DPPH assay).

Non-lamellar lyotropic liquid crystalline nanoparticles as nanocarriers for enhanced drug encapsulation of atorvastatin calcium and proanthocyanidins

Enhancing the biopharmaceutical attributes of atorvastatin calcium using polymeric and lipid-polymer hybrid nanoparticles: An approach for atherosclerosis treatment

Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate (AT-CU) nanoparticles, overcoming the barriers associated with PLGA: An approach for better management of atherosclerosis

Development of Atorvastatin Calcium Biloaded Capsules for Oral Administration of Hypercholesterolemia

Reconstitutable spray dried ultra-fine dispersion as a robust platform for effective oral delivery of an antihyperlipidemic drug

Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability

Synergistic Effects of Liposomes Encapsulating Atorvastatin Calcium and Curcumin and Targeting Dysfunctional Endothelial Cells in Reducing Atherosclerosis

Folic acid-conjugated long circulating co-encapsulated atorvastatin and quercetin solid lipid nanoparticles: pharmacokinetics and biodistribution in rats

Synthesis and Optimization of Chitosan Nanoparticles Loaded with L-Ascorbic Acid and Thymoquinone

Lipid-Polymer Hybrid Nanoparticles Synthesized via Lipid-Based Surface Engineering for a robust drug delivery platform

Multifunctional Dextran Sulfate-Coated Reconstituted High Density Lipoproteins Target Macrophages and Promote Beneficial Antiatherosclerotic Mechanisms

Optimization of transdermal atorvastatin calcium - Loaded proniosomes: Restoring lipid profile and alleviating hepatotoxicity in poloxamer 407-induced hyperlipidemia

Development and Characterization of Binary Solid Lipid Nano Suspension of Atorvastatin: In-Vitro Drug Release and In-Vivo Pharmacokinetic Studies

Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy

Development, optimization, in-vitro , and in-vivo evaluation of chitosan-inlayed nano-spanlastics encompassing lercanidipine HCl for enhancement of bioavailability

Preparation and Characterization of a Lovastatin-Loaded Protein-Free Nanostructured Lipid Carrier Resembling High-Density Lipoprotein and Evaluation of Its Targeting to Foam Cells

Atorvastatin-loaded cubosome: a repurposed targeted delivery systems for enhanced targeting against breast cancer

Lyotropic Liquid Crystal System for Drug Delivery of Astaxanthin: Physical Characterization and Enhanced Antioxidant Potential

Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration

Co-Delivery of Curcumin and Bioperine via PLGA Nanoparticles to Prevent Atherosclerotic Foam Cell Formation

Atorvastatin Calcium and Poly(L-lactide-co-caprolactone) Core-Shell Nanofiber Covered Stent Separating Aneurysm and Promoting Endothelialization